TERT promoter mutations were seen in 8.7% (16/184) of PTMCs and were significantly associated with adverse clinico-pathological characteristics, such as older age (p = 0.0001), extrathyroidal extension (p = 0.0156), DM (p < 0.0001), stage IV tumors (p < 0.0001) and tumor recurrence (p = 0.0048) (Table 3). Here, TERT is linked to neoplasm.